Brendah K. Masisi

University Park
Nottingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Targeting Glutaminase Isoforms GLS and GLS2 in Luminal Breast Cancer.

Targeting Glutaminase Isoforms GLS and GLS2 in Luminal Breast Cancer.

Journal: International journal of molecular sciences

Published: December 15, 2025

Uptake and correlates of modern contraceptive use among women aged 15-49 years in Botswana; evidence from the Botswana demographic survey 2017.

Uptake and correlates of modern contraceptive use among women aged 15-49 years in Botswana; evidence from the Botswana demographic survey 2017.

Journal: Contraception and reproductive medicine

Published: September 26, 2024

Tripartite Motif-Containing 2, a Glutamine Metabolism-Associated Protein, Predicts Poor Patient Outcome in Triple-Negative Breast Cancer Treated with Chemotherapy.

Tripartite Motif-Containing 2, a Glutamine Metabolism-Associated Protein, Predicts Poor Patient Outcome in Triple-Negative Breast Cancer Treated with Chemotherapy.

Journal: Cancers

Published: January 18, 2024

The amino acid transporter SLC7A11 expression in breast cancer.

The amino acid transporter SLC7A11 expression in breast cancer.

Journal: Cancer biology & therapy

Published: December 11, 2023

ATF4 as a Prognostic Marker and Modulator of Glutamine Metabolism in Oestrogen Receptor-Positive Breast Cancer.

ATF4 as a Prognostic Marker and Modulator of Glutamine Metabolism in Oestrogen Receptor-Positive Breast Cancer.

Journal: Pathobiology : journal of immunopathology, molecular and cellular biology

Published: November 20, 2023

The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer.

The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer.

Journal: Cancers

Published: June 09, 2021

SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer.

SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer.

Journal: Breast cancer research and treatment

Published: October 14, 2020

Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer.

Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer.

Journal: Cancers

Published: May 20, 2020

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer.

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer.

Journal: BMC cancer

Published: February 24, 2020

Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.

Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.

Journal: International journal of molecular sciences

Published: January 14, 2020

The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.

The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.

Journal: Breast cancer research and treatment

Published: October 24, 2019

CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.

CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.

Journal: Breast cancer research and treatment

Published: August 14, 2019

Showing 1-12 of 14

Last Updated: 09/26/2026